Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study

NCT05832229 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.

NCT NCT05832229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05832229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase
Phase 2
Overall status
Recruiting
Start date
December 7, 2023
Completion date
August 31, 2029
Enrollment
260 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, cirrhosis advanced, cirrhosis alcoholic, cirrhosis due to hepatitis b, cirrhosis due to hepatitis c, cirrhosis early, cirrhosis infectious, cirrhosis, liver